Clinical Trial Update: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial evaluating Lutetium-177 dotatate ([177Lu]Lu-DOTATATE) versus standard of care for recurrent intracranial meningioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• Lutathera (Lutetium-177 DOTATATE) (Lutetium-177 DOTATATE)

Snippet

Sponsor: RTOG Foundation, Inc. | Conditions: Intracranial Meningioma | Phase 2 | Status: RECRUITING